Related Experiment Videos
Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment
1Duke Clinical Research Center, Duke University Medical Center, Durham, North Carolina 27705, USA.
The American Journal of Cardiology
|June 5, 1999
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
GP IIb/IIIa blockade in elective percutaneous coronary intervention.
Current pharmaceutical design·2004
Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade.
Developments in biologicals·2003
Eptifibatide in percutaneous coronary intervention. A review.
Minerva cardioangiologica·2002
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).
The American journal of cardiology·2001
Procedural Characteristics and Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With and Without Prior CABG.
The American journal of cardiology·2026
Predictors of Perioperative Major Adverse Cardiovascular Events After Bariatric Surgery.
The American journal of cardiology·2026
Risk Factors Associated with Decompensated Heart Failure Following Successful Cardioversion of Atrial Fibrillation and Atrial Flutter: A Validation Cohort.
The American journal of cardiology·2026
Efficacy and Safety of Zalunfiban by Creatinine Clearance Among Patients with ST-Elevation Myocardial Infarction: Analysis from the CELEBRATE Trial.
The American journal of cardiology·2026
Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals.
Handbook of experimental pharmacology·2026
Must RAAS-modifying drugs be withdrawn for the diagnosis of primary aldosteronism?
The Journal of clinical endocrinology and metabolism·2026
Combination Treatment of IL-17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review.
Immunity, inflammation and disease·2026